HGH Frag 176-191 is a modified sequence of the C-terminal end of the human growth hormone (amino acids 176–191), specifically designed to retain the lipolytic (fat-reducing) effects of HGH without influencing blood sugar or IGF-1 levels significantly.

Primary research areas include:

• Fat metabolism enhancement without growth-related side effects

• Reduction of adipose tissue, particularly in abdominal regions

• Improved lipid oxidation and energy use

• Studied for potential support in obesity and metabolic disorders

Unlike full-length HGH, this fragment has shown selectivity for fat-burning pathways, making it a key candidate in body composition and metabolic research.

Disclaimer:

This compound is for laboratory research use only. It is not approved for human consumption, medical, or diagnostic use. All product descriptions are for informational and educational purposes only.